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Abstract Nicotinic cholinergic receptors (nAChRs) form a
heterogeneous family of ligand-gated ion channels found in
the nervous system. The main objective of our research was
to investigate the interaction between cholinergic nicotinic
system and calcium homeostasis in cognitive processes
using the modified elevated plus maze memory model in
mice. The time each mouse took to move from the open arm
to either of the enclosed arms on the retention trial (transfer
latency, TL2) was used as an index of memory. Our results
showed that a single injection of nicotine (0.035 and
0.175 mg/kg) shortened TL2 values, improving memory-
related processes. Similarly, L-type calcium channel antag-
onists (CCAs), i.e., flunarizine, verapamil, amlodipine,
nimodipine, nifedipine, and nicardipine (at the range of dose
5–20 mg/kg) administered before or after training, decreased
TL2 value improving memory acquisition and/or consolida-
tion. Interestingly, at the subthresold doses, flunarizine,
nicardipine, amlodipine, verapamil, and bupropion, a
nAChR antagonist, significantly reversed the nicotine im-
provement of memory acquisition, while flunarizine, verapa-
mil, and bupropion attenuated the improvement of memory
consolidation provoked by an acute injection of nicotine
(0.035 mg/kg, s.c.). After subchronic administration (14 days,
i.p.) of verapamil and amlodipine, two CCAs with the highest
affinity for nAChRs, only verapamil (5 mg/kg) impaired
memory acquisition and consolidation while both verapamil
and amlodipine, at the subthresold, ineffective dose
(2.5 mg/kg), significantly reversed the improvement of mem-
ory provoked by an acute injection of nicotine (0.035 mg/kg,
s.c.). Our findings can be useful to better understand the
interaction between cholinergic nicotinic receptors and
calcium-related mechanisms in memory-related processes.
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Introduction
Neuronal nicotinic cholinergic receptors (nAChRs) form a
heterogeneous family of ligand-gated ion channels found in
the central and peripheral nervous system that regulate syn-
aptic activity (Jackson et al. 2008; Picciotto et al. 2000;
Stolerman and Shoaib 1991; Wonnacott 1997). Numerous
subtypes of nAChRs have been identified and many of them
were recognized to be involved in specific neurological and
physiological behaviors. For instance, α3β2 nAChR plays a
role in dopamine release and Parkinson’s disease, α3β4
regulates noradrenaline release and cardiovascular or gas-
trointestinal action, and α9 was found important in devel-
opment of auditory functions. Moreover, the most abundant
subtypes of the nAChRs in the cortex, i.e., α4β2, α4β4,
and α7 are involved in memory, learning, and sensory
gating functions (Gotti et al. 2006).
nAChRs are activated by endogenous acetylcholine
(ACh) and the group of ortosteric agonists, such as nicotine,
while their activity is inhibited by a diverse group of com-
petitive antagonists. Except for these actions, different sub-
types of nAChR can be modulated allosterically by various
endogenous [e.g., substance P, serotonin (5-HT), fatty acids,
steroids or β-amyloid] as well as exogenous (e.g., alkaloids,
venom toxins, alcohol, and other drugs) substances with
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different binding sites on the nAChRs (Moaddel et al.
2007). In fact, over 50 marketed drugs belonging to different
therapeutic classes exert allosteric positive (noncompetitive
agonists) or allosteric negative (noncompetitive antagonists)
modulation on nAChRs, and many of these actions are
subtype specific. For a long time, these off-target interactions
did not attract significant recognition up to recently when
modulation of nAChRs is being linked to specific adverse
effects observed during certain therapies (Friederich et al.
2000). For example, constipation induced by verapamil or
methadone is regarded to be a result of strong inhibition of
specific subtypes of nAChRs.
The main nAChRs serve as potential therapeutic targets
for a many different diseases (Bencherif and Schmitt 2002;
Buccafusco 2004). For example, nicotine and other nAChR
agonists with differential subtype selectivity have been iden-
tified as potential cognition-enhancing therapeutic drugs,
particularly for the treatment of Alzheimer’s disease (AD)
(Bencherif and Schmitt 2002; Buccafusco 2004; Levin
2002; Moaddel et al. 2007; Picciotto and Zoli 2002). It has
been commonly accepted that the progressive loss of cho-
linergic neurons is one of the cornerstone of AD pathology,
and the association between nAChR and cognitive decline
in AD has been widely investigated. For the past several
years, a mainstay of the AD therapy has been aimed at
inhibiting acetylcholinesterase and thereby increasing ACh
levels in the central nervous system. Three such inhibitors,
donepezil, galantamine, and rivastigmine, are now in clini-
cal practice for treatment of mild and moderate AD.
Currently, selective activation of α4β2 and/or α7 nAChRs
is also under investigation as a therapeutic strategy in AD
treatment and several such agonists are in clinical trials
(Moaddel et al. 2007).
As already mentioned, nicotine itself shows neuro-
protective properties and several epidemiological studies
claim a lower incidence of AD in tobacco habitual smokers;
the latter statement, however, is in conflict with some other
more recent reports (Levin 2002; Picciotto and Zoli 2002;
Sabbagh et al. 2002). All of them suggest that exogenous
modulation of the subtypes of nAChRs, especially in the
longer time frame, has an impact on cognitive functions in
elderly people and development of AD symptoms.
Additionally, studies on several aging populations indicate
the higher risk of dementia and/or AD in hypertension
patients treated with certain calcium channel antagonists
(CCAs) comparing to those treated with other hypotensive
drugs (Maxwell et al. 1999; Khachaturian et al. 2006).
Accordingly, it has been recently suggested that many com-
monly used CCAs can be strong noncompetitive inhibitors
for the α3β4 subtype of nAChRs (Jozwiak et al. 2005,
2008). Several clinical and experimental studies have al-
ready evaluated the potential of antihypertensive medica-
tions for modification of the risk of AD. In this large
population-based study of persons aged 65 years and older,
the authors found reduced risks of AD among subjects using
specific types of medications (Khachaturian et al. 2006).
Suggestive trends were observed with beta-blockers and
dihydropyridine CCAs independently of their ability to
control blood pressure. On the other hand, concern has
been raised about the potential for adverse cognitive
effects associated with the use of CCAs in older people
who, according to other author, were significantly more
likely than those using other agents to experience cog-
nitive decline (Khachaturian et al. 2006, for review).
Considering the results mentioned above supported by
evidence from epidemiological studies, we intended to fur-
ther investigate the effect of nicotine on memory-related
behavior as well as the interaction between cholinergic
nicotinic system and calcium homeostasis in cognitive pro-
cesses using the recently developed modified elevated plus
maze (mEPM) memory model in mice (Biala and Kruk
2008; Itoh et al. 1990; Kruk et al. 2011; Kruk-Slomka et
al. 2012). Recently, this test, originally developed to esti-
mate anxiety in rodents, was modified to evaluate spatial
learning and memory. Briefly, this simple method consists
of measuring of the time necessary for the animal to move
from the open to the enclosed arm, i.e., the transfer latency
(TL). This protocol demonstrates that the information ac-
quired in the first trial is consolidated within 24 h after the
acquisition session and successfully recalled during the sec-
ond trial. A reduction in TL using the retention trial
followed 24 h represents an improvement in learning and
memory and has been interpreted as the ability for animals
to remember the location of the enclosed arms and escape
from the unsafe open and high space faster on the second
retention trial. On the contrary, increases in TL during
retention testing could be used to indicate impairments in
memory induced by drugs that possess amnesic properties.
This method has been successfully used in studies investi-
gating the involvement of different neurotransmitter systems,
including cholinergic pathways, on learning and memory
processes. For instance, amnesic properties of scopolamine,
a muscarinic receptor antagonist, were evaluated. Indeed,
scopolamine increased the TL time, while physostigmine
decreased the TL values on the second retention trial and
reversed the effects of scopolamine (Hliňák and Krejčí 1998,
2002; Itoh et al. 1991; Sharma and Kulkarni 1992).
Based on previous experiments in vitro (Jozwiak et al.
2005, 2008), the characterization of drug action was then
performed to qualify substances for in vivo animal test. For
this purpose, in continuation of our efforts to understand the
neurobiology of memory and learning processes, we inves-
tigated the influence of acute and subchronic administration
of CCAs on the acquisition and consolidation of memory-
related processes as well as on the memory enhancing
effects of nicotine. To this end, L-type voltage-dependent
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calcium channel (VDCC) antagonists of various classes in-
cluding dihydropyridines (e.g., nimodipine, nifedipine,
nicardipine, amlodipine), phenylalkylamines (e.g., verapa-
m i l ) , b enzo t h i a z ep i n e s ( e . g . , d i l t i a z em) , and
diphenylalkylamines (e.g., flunarizine) were used. The range
of doses and timingwas selected taking into account studies of
behavioral effects of VDCC blockers conducted on rodents
and obtained previously in our laboratory (Biala 2003; Biala
and Budzynska 2006, 2008; Biala and Weglinska 2004,
2005). Accordingly, at these doses, the drugs did not affect
locomotor activity measured either in the EPM test or in the
actimeter cages. We have chosen these different classes of
compounds as the results, including those of our group
already cited, indicate that various classes of calcium antag-
onists differ in their interaction with the effects of psychoac-
tive substances as well with nAChR subtypes. In comparison
with our previous study describing memory-related effects of
CCAs and nicotine, in the present new and original study,
larger range of doses of seven selected compounds was used,
both acute and repeated CCAs injections and, importantly,
both stages of memory, i.e., acquisition and consolidation
also in the context of possible influence on nicotine cognitive
effects, were studied. The following criteria were used to
select compounds for these experiments: (a) drugs common-
ly used for chronic treatment, especially in cardiovascular
disorders, (b) strong modulators of subtypes of receptor
involved in AD development (α2β2, α2β4, and α7), and
(c) drugs, for which epidemiological data suggest an in-
creased (or decreased) risk of AD incidence in patients with
the long term treatment history. Our study can be useful to
better understand the common cholinergic/calcium-depen-
dent mechanisms of memory formation and may provide
new perspectives for the promising therapy of human disor-
ders, in which cholinergic signaling has been implicated,
including AD, dementia, and addiction.
Materials and methods
Animals
The experiments were carried out on naive male Swiss mice
(Farm of Laboratory Animals, Warszawa, Poland), about
1 month old, weighing 20–30 g. The animals were
maintained under standard laboratory conditions (12-h
light/dark cycle; room temperature, 21±1 °C; 40–50 %
humidity) with free access to tap water and laboratory chow
(Bacutil, Motycz, Poland) in their home cages and were
adapted to the laboratory conditions for at least 1 week
before the experiments. Each experimental group consisted
of 8–15 animals. Before and during the experiments, ani-
mals were kept in group consisting of 10 animals. The total
number of animals used in all experiments was about 930.
All behavioral experiments were performed between
0800 and 1400 hours and were conducted according to the
National Institute of Health Guidelines for the Care and Use
of Laboratory Animals and the European Community
Council Directive for the Care and Use of Laboratory
Animals of 24 November 1986 (86/609/EEC). All experi-
ments were approved by the local ethics committee (license
no. 25/2008).
Drugs
The following compounds were tested: (−)-nicotine hydro-
gen tartrate (0.0175, 0.035, 0.175, or 0.35 mg/kg, reported
in freebase nicotine weight; Sigma-Aldrich, St. Louis, MO,
USA), bupropion hydrochloride (10, 20, and 40 mg/kg,
Sigma-Aldrich, St. Louis, MO, USA), verapamil hydrochlo-
ride (2.5, 5, 10, or 20 mg/kg, Sigma-Aldrich, St. Louis, MO,
USA), diltiazem hydrochloride (5, 10, or 20 mg/kg, Sigma-
Aldrich, St. Louis, MO, USA), amlodipine besylate (2.5, 5,
10, or 20 mg/kg, Sigma-Aldrich, St. Louis, MO, USA),
flunarizine dihydrochloride (5, 10, or 20 mg/kg, Sigma-
Aldrich, St. Louis, MO, USA), nimodipine (5, 10, or
20 mg/kg, Sigma-Aldrich, St. Louis, MO, USA),
nicardipine hydrochloride (2.5, 5, 10, or 20 mg/kg, Sigma-
Aldrich, St. Louis, MO, USA), and nifedipine (5, 10, or
20 mg/kg, Sigma-Aldrich, St. Louis, MO, USA). All com-
pounds were dissolved in saline solution (0.9 % NaCl).
Except for nicotine, the drug doses refer to the salt form.
The pH of the nicotine solution was adjusted to 7.0. Fresh
drug solutions were prepared on each day of experimenta-
tion. All agents were administered subcutaneously (s.c.) or
intraperitoneally (i.p.) at a volume of 10 ml/kg. Control
groups received saline injections of the same volume and
via the same route of administration.
Apparatus and experimental procedures
Memory and learning responses were measured using the
mEPM test as described previously (Biala and Kruk 2008;
Kruk et al. 2011). The experimental apparatus was shaped
like a “plus” sign and consisted of a central platform (5×
5 cm), two open arms (5×30 cm), and two enclosed arms
(5×30×15 cm) opposite to each other. The maze was made
of dark Plexiglas. The whole apparatus was elevated 50 cm
above the floor, kept in a soundproof room with a neutral
masking noise and a dim 40 lx illumination.
In the mEPM test, the time that the mice took to move
from the open arm to the enclosed arm was used as the index
of learning and memory and defined as TL. The mice were
placed individually at the end of the open arm, facing it
away from the central platform. Each group was submitted
to the same procedure twice (the interval between the trials
was 24 h). On the first trial (acquisition trial), the time each
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mouse took to move from the open arm to either of the
enclosed arms (transfer latency, TL1) was observed on a
monitor through a video camera system and recorded by the
experimenter blind to the experimental group. If the mice
failed to enter the enclosed arm within 90 s, they were
placed at an enclosed arm and permitted to explore the plus
maze for additional 60 s. In such a case, the TL1 value was
recorded as 90 s. On the next trial (retention trial), 24 h later,
the test was performed in the same manner as the first trial
and the TL was recorded (TL2). If the mouse did not enter
the enclosed arm within 90 s, the test was stopped, and the
TL2 was recorded as 90 s. Any animal that fell off the maze
was excluded from the experiment. In the mEPM test, we
used the TL2 values on the retention trial as an index of
memory and learning effects. Entry into one arm was
recorded when an animal placed all four paws past the line
dividing the central square from the open arms. The test
arena was wiped with a damp cloth after each trial.
The mEPM task allows investigating different stages of
memory, depending on the time of drug treatment. Thus,
administration of the drug before the first trial (before pre-
test) should interfere with the acquisition of information,
while its administration immediately after the first trial (after
pretest) should affect the processes of consolidation. In our
experiments, the drugs were administered 30 min before the
pretest or immediately after the pretest, and the effects of
each compound on memory acquisition and consolidation
were investigated.
Treatment
The first experiment was designed to investigate the influ-
ence of either nicotine or CCAs on memory-related re-
sponses using the mEPM in mice. Nicotine (0.0175, 0.035,
0.175, and 0.35 mg/kg, s.c.), verapamil (2.5, 5, 10, and
20 mg/kg, i.p.), diltiazem (5, 10, and 20 mg/kg, i.p.),
amlodipine (2.5, 5, 10, and 20 mg/kg, i.p.), flunarizine (5,
10, and 20 mg/kg, i.p.), nimodipine (5, 10, and 20 mg/kg,
i.p.), nicardipine (2.5, 5, 10, and 20 mg/kg, i.p.), nifedipine
(5, 10, and 20 mg/kg, i.p.), bupropion (10, 20, and
40 mg/kg), for comparison, or saline were administered
30 min before the first trial (memory acquisition) or imme-
diately after the first trial (memory consolidation). Twenty-
four hours later, the animals were retested in the mEPM test.
This second day, the mice did not receive any injection.
The second set of experiments was designed to investi-
gate the influence of acute CCAs administration, at the
inactive doses, on the acquisition and consolidation of
memory-related responses induced by acute nicotine admin-
istration. For this purpose, verapamil (2.5 mg/kg, i.p.),
amlodipine (2.5 mg/kg, i.p.), flunarizine (5 mg/kg, i.p.),
nicardipine (2.5 mg/kg, i.p.), and bupropion (10 and
20 mg/kg, i.p.) or saline were administered 15 min prior to
effective dose of nicotine (0.035 mg/kg, s.c.), and then the
mice were tested 30 min later and retested after 24 h (mem-
ory acquisition) in the mEPM test. Additional groups of
mice were injected as described above, but immediately
after the first trial. The animals were then retested after
24 h (memory consolidation) in the mEPM test.
In the next set of experiments, we evaluated the influence
of chronic CCAs (i.e., verapamil and amlodipine) adminis-
tration on the acquisition and consolidation of memory-
related responses using the mEPM in mice. For this purpose,
the mice were randomly allocated to receive 13 days of i.p.
injections of verapamil (2.5 and 5 mg/kg), amlodipine (2.5
and 5 mg/kg), or saline (for the control group). After an
additional injection on the 14th day, the mice were tested
30 min later and retested after 24 h (memory acquisition) in
the mEPM test. The remaining group of mice were also
injected with verapamil (2.5 and 5 mg/kg, i.p.), amlodipine
(2.5 and 5 mg/kg, i.p.), or saline immediately after the first
trial. These animals were then retested after 24 h (memory
consolidation).
The last experiment was designed to examine the influ-
ence of above-mentioned chronic CCAs administration on
the acquisition and consolidation of memory-related re-
sponses induced by an acute nicotine injection. For this
purpose, verapamil (2.5 mg/kg, i.p.), amlodipine (2.5 mg/kg,
i.p.), or saline were administered for 13 days. On the 14th
day, some animals were subjected to verapamil (2.5 mg/kg,
i.p.), amlodipine (2.5 mg/kg, i.p.), or saline, 15 min prior to
acute nicotine (0.035 mg/kg, s.c.) administration. Then, the
mice were tested 30 min later and retested after 24 h (mem-
ory acquisition) in the mEPM test. The remaining group of
mice was injected as described above, but immediately after
the first trial. These animals were then retested after 24 h
(memory consolidation).
Statistics
The data were expressed as the means±SEM. For the
mEPM test, we measured TL, i.e., the time necessary for
the mice to move from the open arm to either of the enclosed
arms. The statistical analyses were performed using the one-
way analyses of variance (ANOVA). A post hoc comparison
of means was carried out using Tukey’s test for multiple
comparisons, when appropriate. The data were considered
statistically significant at a confidence limit of P<0.05.
Results
Across all experiments, the time (in seconds) that each
mouse took to move from the open arm to either of the
enclosed arms on the first trial (pretest), i.e., TL1, did not
significantly differ among groups. Moreover, nicotine,
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CCAs or bupropion administered before this first trial had
no influence on TL1 values across experiments (Table 1).
Influence of acute nicotine, CCAs, or bupropion
administration on memory-related processes in the mEPM
model in mice
One-way ANOVA revealed that acute s.c. doses of nicotine
(0.0175, 0.035, 0.175, or 0.35 mg/kg) and acute i.p. doses of
CCAs used, i.e., amlodipine, flunarizine, nimodipine,
nicardipine, verapamil, diltiazem (2.5–20 mg/kg), or
bupropion (10–40 mg/kg) had a statistically significant effect
on TL2 values [F(31,308)=6.103; P<0.0001], with respect
to memory acquisition during the retention trial. Indeed, post
hoc Tukey’s test revealed that the mice treated with nicotine
(0.035 and 0.175 mg/kg), amlodipine (5, 10, and 20 mg/kg),
nicardipine (5, 10, and 20mg/kg), and flunarizine (20 mg/kg)
significantly decreased TL2 values compared with saline-
treated mice, indicating that these compounds improved
memory and learning acquisition processes (P<0.05 for
nicardipine and flunarizine; P<0.001 for nicotine and
amlodipine; Table 2).
Table 1 Effects of acute nicotine, bupropion, CCAs, or saline injec-
tion on the transfer latency to the enclosed arm on the first trial (TL1)
using the mEPM test in mice
Compound TL 1
Saline 59.00±7.78
Nicotine 0.0175 mg/kg 47.80±15.23
Nicotine 0.035 mg/kg 51.20±10.21
Nicotine 0.175 mg/kg 45.10±9.15
Nicotine 0.35 mg/kg 50.33±4.35
Bupropion 10 mg/kg 43.10±4.41
Bupropion 20 mg/kg 45.00±2.51
Bupropion 40 mg/kg 50.10±7.20
Amlodipine 2.5 mg/kg 43.60±4.35
Amlodipine 5 mg/kg 52.60±5.83
Amlodipine 10 mg/kg 36.40±6.04
Amlodipine 20 mg/kg 36.80±4.63
Flunarizine 5 mg/kg 48.33±5.39
Flunarizine 10 mg/kg 51.20±5.84
Flunarizine 20 mg/kg 42.93±4.98
Nimodipine 5 mg/kg 41.50±8.44
Nimodipine 10 mg/kg 49.20±6.31
Nimodipine 20 mg/kg 42.50±4.51
Nifedipine 5 mg/kg 42.20±7.43
Nifedipine 10 mg/kg 47.40±7.86
Nifedipine 20 mg/kg 44.80±9.22
Nicardipine 2.5 mg/kg 49.13±3.98
Nicardipine 5 mg/kg 52.50±5.34
Nicardipine 10 mg/kg 53.60±8.06
Nicardipine 20 mg/kg 49.20±7.39
Verapamil 2.5 mg/kg 58.90±7.61
Verapamil 5 mg/kg 52.50±7.22
Verapamil 10 mg/kg 55.90±4.69
Verapamil 20 mg/kg 44.67±10.44
Diltiazem 5 mg/kg 55.31±6.15
Diltiazem 10 mg/kg 48.80±4.70
Diltiazem 20 mg/kg 47.75±6.45
Nicotine, bupropion, CCAs, or saline were administered 30 min before
the first trial; n=8–15; the data are shown as the means±SEM
Table 2 Effects of acute nicotine, bupropion, CCAs, or saline injec-
tion on the transfer latency to the enclosed arm in the acquisition trial
using the mEPM test in mice
Compound TL2
Saline 33.60±3.30
Nicotine 0.0175 mg/kg 25.30±4.75
Nicotine 0.035 mg/kg 12.79±1.14**
Nicotine 0.175 mg/kg 11.75±2.08**
Nicotine 0.35 mg/kg 25.50±5.35
Bupropion 10 mg/kg 51.75±6.29
Bupropion 20 mg/kg 38.70±4.94
Bupropion 40 mg/kg 41.20±8.72
Amlodipine 2.5 mg/kg 29.60±4.41
Amlodipine 5 mg/kg 15.10±1.71**
Amlodipine 10 mg/kg 11.40±1.28**
Amlodipine 20 mg/kg 7.20±1.06**
Flunarizine 5 mg/kg 22.67±6.12
Flunarizine 10 mg/kg 28.07±4.38
Flunarizine 20 mg/kg 14.71±2.50*
Nimodipine 5 mg/kg 39.80±2.45
Nimodipine 10 mg/kg 30.60±3.02
Nimodipine 20 mg/kg 25.10±3.83
Nifedipine 5 mg/kg 26.30±5.08
Nifedipine 10 mg/kg 23.00±2.67
Nifedipine 20 mg/kg 26.70±3.61
Nicardipine 2.5 mg/kg 29.50±5.57
Nicardipine 5 mg/kg 22.20±3.31*
Nicardipine 10 mg/kg 22.40±2.19*
Nicardipine 20 mg/kg 22.10±2.45*
Verapamil 2.5 mg/kg 45.00±6.03
Verapamil 5 mg/kg 29.90±4.44
Verapamil 10 mg/kg 31.50±4.27
Verapamil 20 mg/kg 20.67±3.68
Diltiazem 5 mg/kg 16.69±3.49
Diltiazem 10 mg/kg 30.40±4.00
Diltiazem 20 mg/kg 49.75±7.83
Nicotine, bupropion, CCAs, or saline were administered 30 min before
the first trial; n=8–15; the data are shown as the means±SEM
*P<0.05; **P<0.001 vs. saline-treated group (Tukey’s test)
Naunyn-Schmiedeberg's Arch Pharmacol (2013) 386:651–664 655
Similarly, for memory consolidation during the retention
trial, the mice receiving acute s.c. doses of nicotine (0.0175,
0.035, 0.175, or 0.35 mg/kg) and acute i.p. doses of CCAs
used, i.e., amlodipine, flunarizine, nimodipine, nicardipine,
verapamil, diltiazem (2.5–20 mg/kg), or bupropion (10–
40 mg/kg) had a statistically significant effect on TL2 values
[F(31,308)=4.660; P<0.0001]. Indeed, post hoc Tukey’s
test revealed that the mice treated with nicotine (0.035 and
0.175 mg/kg), amlodipine (5, 10, and 20 mg/kg),
nimodipine (20 mg/kg), nifedipine (10 and 20 mg/kg), and
verapamil (5 and 10 mg/kg) significantly decreased TL2
values compared with saline-treated mice, indicating that
these compounds improved memory and learning consoli-
dation processes (P<0.05 for nicotine and amlodipine
10 mg/kg; P<0.01 for nimodipine, nifedipine, verapamil,
and amlodipine 5 and 20 mg/kg; Table 3).
Influence of acute CCAs or bupropion administration
on memory-related responses induced by an acute nicotine
using the mEPM model in mice
Figure 1a shows the effect of pretraining of flunarizine
(5 mg/kg), nicardipine (2.5 mg/kg), amlodipine (2.5 mg/kg),
verapamil (2.5 mg/kg), or bupropion (10 and 20 mg/kg),
i.p., on the improvement of memory acquisition induced by
nicotine (0.035 mg/kg, s.c.) injection. One-way ANOVA
revealed that there was a statistically significant effect
[F(6,63)=3.905, P=0.0022], with respect to memory ac-
quisition during the retention trial. In this experiment,
flunarizine, nicardipine, amlodipine, verapamil, and
bupropion, at the subthresold doses, significantly reversed
the improvement of memory provoked by an acute injec-
tion of nicotine, thus resulting in an increased TL2 time
compared to the nicotine-treated group (P<0.05 for
nicardipine, verapamil, and bupropion 10 mg/kg; P<0.01
for bupropion 20 mg/kg; P<0.001 for flunarizine and
amlodipine, Tukey’s test; Fig. 1a).
Similarly, Fig. 1b shows the effect of pretreatment of
flunarizine (5 mg/kg), nicardipine (2.5 mg/kg), amlodipine
(2.5 mg/kg), verapamil (2.5 mg/kg), or bupropion (10 and
20 mg/kg), i.p., on the improvement of memory consolida-
tion induced by nicotine (0.035 mg/kg, s.c.) injection. One-
way ANOVA revealed that there was a statistically signifi-
cant effect [F(6,63)=7.223, P<0.0001], with respect to
memory consolidation during the retention trial. In this
experiment, flunarizine, verapamil, and bupropion, but
not nicardipine or amlodipine, at the subthresold doses,
significantly reversed the improvement of memory pro-
voked by an acute injection of nicotine, thus resulting in
an increased TL2 time compared to the nicotine-treated
group (P<0.05 for flunarizine and bupropion 10 mg/kg;
P<0.01 for verapamil and bupropion 20 mg/kg, Tukey’s
test; Fig. 1b).
Influence of chronic CCAs administration on memory-related
processes in the mEPM model in mice
One-way ANOVA revealed that chronic i.p. administration
of verapamil (2.5 and 5 mg/kg) and amlodipine (2.5 and
5 mg/kg) had a statistically significant effect on TL2 values
[F(4,35)=2.902, P=0.0357], with respect to memory acqui-
sition during the retention trial. Indeed, post hoc Tukey’s
test revealed that mice treated only with verapamil (5 mg/kg)
significantly increased TL2 values compared with saline-
treated mice, indicating that verapamil, at this dose used,
Table 3 Effects of an acute nicotine, bupropion, CCAs, or saline
injection on the transfer latency to the enclosed arm in the consolida-
tion trial using the mEPM test in mice
Compound TL2
Saline 36.50±9.08
Nicotine 0.0175 mg/kg 42.00±5.12
Nicotine 0.035 mg/kg 17.36±1.14*
Nicotine 0.175 mg/kg 13.86±1.58*
Nicotine 0.35 mg/kg 23.50±2.80
Bupropion 10 mg/kg 51.78±5.39
Bupropion 20 mg/kg 46.00±8.82
Bupropion 40 mg/kg 36.44±5.36
Amlodipine 2.5 mg/kg 39.80±7.60
Amlodipine 5 mg/kg 13.00±1.13**
Amlodipine 10 mg/kg 14.70±1.65*
Amlodipine 20 mg/kg 10.10±0.88**
Flunarizine 5 mg/kg 25.80±5.49
Flunarizine 10 mg/kg 20.73±3.28
Flunarizine 20 mg/kg 24.93±4.56
Nimodipine 5 mg/kg 36.10±2.18
Nimodipine 10 mg/kg 28.00±2.67
Nimodipine 20 mg/kg 16.50±1.60**
Nifedipine 5 mg/kg 22.20±3.48
Nifedipine 10 mg/kg 14.30±3.22**
Nifedipine 20 mg/kg 14.60±1.97**
Nicardipine 2.5 mg/kg 24.70±9.27
Nicardipine 5 mg/kg 29.60±7.35
Nicardipine 10 mg/kg 23.40±3.31
Nicardipine 20 mg/kg 28.40±7.27
Verapamil 2.5 mg/kg 32.50±3.15
Verapamil 5 mg/kg 12.30±1.22**
Verapamil 10 mg/kg 15.50±2.45**
Verapamil 20 mg/kg 23.60±3.61
Diltiazem 5 mg/kg 31.23±5.71
Diltiazem 10 mg/kg 22.27±2.08
Diltiazem 20 mg/kg 28.33±4.98
Nicotine, bupropion, CCAs, or saline were administered immediately
after the first trial; n=8–15; the data are shown as the means±SEM
*P<0.05; **P<0.01 vs. saline-treated group (Tukey’s test)
656 Naunyn-Schmiedeberg's Arch Pharmacol (2013) 386:651–664
impaired memory and learning processes after subchronic
administration (P<0.05; Table 4). Similarly, for memory
consolidation during the retention trial, the mice receiving
chronic CCAs administration had significantly increased
TL2 values compared to the saline-treated mice [F(4,35)=
2.727, P=0.0447]. Additionally, post hoc Tukey’s test re-
vealed a statistically significant effect (P<0.05; Table 5),
indicating that only verapamil (5 mg/kg), at this dose used,
impaired this stage of memory and learning processes after
subchronic administration.
Influence of chronic CCAs administration on memory-related
responses induced by acute nicotine using the mEPM model
in mice
Figure 2a shows the effect of chronic verapamil pre-
treatment (2.5 mg/kg) on the memory improvement induced
by acute nicotine injection. For memory acquisition during
the retention trial, one-way ANOVA revealed a statistically
significant effect on TL2 values [F(4,38)=9.406, P<
0.0001]. In this experiment, verapamil at the subthresold,
ineffective dose, significantly reversed the improvement of
memory provoked by an acute injection of nicotine
(0.035 mg/kg), thus resulting in an increased TL2 time
compared with saline-treated and nicotine challenged group
(P<0.001, Tukey’s test). Likewise, for memory consolida-
tion during the retention trial, one-way ANOVA revealed
Table 4 Effects of chronic CCAs or saline administration on the
transfer latency to the enclosed arm in the acquisition trial using the
mEPM test in mice
Compound TL2
Saline 22.00±3.50
Verapamil 2.5 mg/kg 32.37±7.02
Verapamil 5 mg/kg 47.25±5.57*
Amlodipine 2.5 mg/kg 36.25±6.22
Amlodipine 5 mg/kg 26.75±5.45
Verapamil (2.5 and 5 mg/kg, i.p.), amlodipine (2.5 and 5 mg/kg), or
saline were administered for 13 days. On the 14th day, the mice were
injected with CCAs or saline 30 min before the first trial; n=8–10; the
data are shown as the means±SEM



















































































































Fig. 1 Influence of an acute CCAs or bupropion administration on the
memory-related responses induced by an acute nicotine injection in the
acquisition trial (a) or consolidation trial (b) using the mEPM test in
mice. Flunarizine (5 mg/kg, i.p.), nicardipine (2.5 mg/kg, i.p.),
amlodipine (2.5 mg/kg, i.p.), verapamil (2.5 mg/kg, i.p.), bupropion
(10 and 20 mg/kg, i.p.), or saline were administered 15 min prior to
saline or nicotine (0.035 mg/kg, s.c.) injection, 30 min before the first
trial (a) or immediately after the first trial (b); n=8–14; the data are
shown as the means±SEM; ^P<0.05; ^^P<0.01; ^^^P<0.001 vs.
nicotine-treated group (Tukey’s test)
Table 5 Effects of chronic CCAs or saline administration on the
transfer latency to the enclosed arm in the consolidation trial using
the mEPM test in mice
Compound TL2
Saline 26.62±5.32
Verapamil 2.5 mg/kg 48.00±7.46
Verapamil 5 mg/kg 55.87±10.31*
Amlodipine 2.5 mg/kg 40.87±8.53
Amlodipine 5 mg/kg 27.62±5.83
Verapamil (2.5 and 5 mg/kg, i.p.), amlodipine (2.5 and 5 mg/kg), or
saline were administered for 13 days. On the 14th day, the mice were
injected with CCAs or saline 30 min immediately after the first trial;
n=8–10; the data are shown as the means±SEM
*P<0.05 vs. saline-treated group (Tukey’s test)
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statistically significant effect [F(4,39)=8.229, P<0.0001)].
Indeed, post hoc Tukey’s test revealed that verapamil, at this
subthresold, ineffective dose, significantly reversed the im-
provement of memory provoked by an acute injection of
nicotine, thus resulting in an increased TL2 time compared
with saline-treated and nicotine challenged group (P<0.05;
Fig. 2b).
In turn, Fig. 3a shows the effect of chronic amlodipine
pretreatment (2.5 mg/kg) on the memory improvement in-
duced by acute nicotine injection. For memory acquisition
during the retention trial, one-way ANOVA revealed a sta-
tistically significant effect on TL2 values [F(4,37)=5.052;
P<0.0024]. In this experiment, amlodipine at this ineffec-






























































































































































Fig. 2 Influence of verapamil administered chronically on the memo-
ry-related responses induced by an acute nicotine administration in the
acquisition trial (a) or consolidation trial (b) using the mEPM test in
mice. Verapamil (2.5 and 5 mg/kg, i.p.) or saline was administered for
13 days. On the 14th day, the mice were injected with verapamil
(2.5 mg/kg) or saline 15 min prior to saline or nicotine (0.035 mg/kg,
s.c.) injection, 30 min before the first trial (a) or immediately after the
first trial (b); n=8–10; the data are shown as the means±SEM; ^P<
0.05; ^^^P<0.001 vs. saline-treated and nicotine-challenged group; *P






















































































































































Fig. 3 Influence of amlodipine administered chronically on the mem-
ory-related responses induced by an acute nicotine administration in
the acquisition trial (a) or consolidation trial (b) using the mEPM test
in mice. Amlodipine (2.5 and 5 mg/kg, i.p.) or saline were adminis-
tered for 13 days. On the 14th day, the mice were injected with
amlodipine (2.5 mg/kg) or saline 15 min prior to saline or nicotine
(0.035 mg/kg, s.c.) injection, 30 min before the first trial (a) or
immediately after the first trial (b); n=8–10; the data are shown as
the means±SEM; ^P<0.05 vs. saline-treated and nicotine-challenged
group; *P<0.05; **P<0.01 vs. saline-treated group (Tukey’s test)
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provoked by an acute injection of nicotine (0.035 mg/kg),
thus resulting in an increased TL2 time compared with
saline-treated and nicotine challenged group (P<0.05,
Tukey’s test). Similarly, for memory consolidation during
the retention trial, one-way ANOVA revealed that there was
statistically significant effect [F(4,37)=4.391; P=0.0053)].
Indeed, post hoc Tukey’s test revealed that amlodipine, at
the ineffective dose of 2.5 mg/kg, significantly reversed the
improvement of memory provoked by an acute injection of
nicotine, thus resulting in an increased TL2 time compared
with saline-treated and nicotine challenged group (P<0.05;
Fig. 3b).
Discussion
In the present study, we intended to investigate the effect of
nicotine on memory-related behavior as well as the influence
of acute and/or subchronic administration of different CCAs,
at the large range of doses, on the acquisition and consolida-
tion of memory-related processes and the procognitive ef-
fects of nicotine using the recently developed mEPM
memory model in mice. Our data extend present knowledge
about the influence of pharmacological blockade of L-type
VDCC on memory and learning processes in the context of
possible interactions with cholinergic transmission.
It has been well documented that nicotine, an alkaloid
present in tobacco, is responsible for pharmacological ac-
tions of smoking and for its addictive effects, including
drug-seeking and relapse despite harmful effect (Dani and
De Biasi 2001; Di Chiara 2000; Zaniewska et al. 2009).
Nicotine action is due to the activation of different types of
the nAChRs in the midbrain dopaminergic reward pathway,
especially in the ventral tegmental area (VTA) (Maskos et
al. 2005; Stolerman and Shoaib 1991). Moreover, nicotine,
as the prototypical nonselective agonist for nAChRs, has
long been known to possess procognitive activity in human
smokers and nonsmokers (Levin 2002; Levin and Rezvani
2000). The above-mentioned property of nicotine may be of
therapeutic benefit in chronic disease states, such as
AD, Parkinson’s disease, schizophrenia, or attention-
deficit/hyperactivity disorder (Bencherif and Schmitt 2002;
Buccafusco 2004; Leonard and Bertrand 2001; Newhouse et
al. 1997). However, the side-effect profile of nicotine, e.g.,
its addictive and psychomotor stimulant properties, pre-
cludes the clinical use of this compound or of its analogs.
In experimental animals, nicotine has been found to
improve cognitive behavior, although other studies have
not found improvements; on the contrary, some have found
memory impairments (Biala and Kruk 2008; Hefco et al.
2003; Levin et al. 2006; Puma et al. 1999; Rezvani and
Levin 1998). Some of the differences in findings appear to
be due to the dose used or the type of cognitive model.
Experiments emphasizing nicotine ability to enhance mem-
ory and learning, including acquisition, consolidation, and
retention, have been performed, both in laboratory animals
and humans, and it seems to result from activation of central
nAChRs in the prefrontal cortex, hippocampus, and amyg-
dala (Levin and Rezvani 2000; Levin and Simon 1998).
Activation of these receptors provokes the release of several
neurotransmitters, including dopamine, noradrenaline, 5-
HT, ACh, gamma-aminobutyric acid, glutamate, and hista-
mine (Wonnacott 1997), important in the regulation of
memory processes. Many of nicotine-related behavioral ef-
fects, including memory responses, can be characterized by
a dose-dependent inverted U-shaped correlation, as con-
firmed in our study. It means that, when a particular dose
of nicotine is exceed, nicotine-induced responses diminish
rapidly. It is specific to the higher nicotine doses, which
induce little neuronal activation in many neuronal structures,
e.g., the NAC, amygdala, and other limbic areas such as the
septum, hippocampus, and hypothalamus. Responsible for
this nicotine biphasic pattern of action is acute nicotine
tolerance and related desensitization of nicotinic receptors
(Wang and Sun 2005).
As noted above, nicotine is a nonselective agonist for all
nAChR subtypes, but two subtypes mainly expressed in the
brain are of major interest in this context: the heteromeric
α4β2, α3β4 and the homomeric α7 (Marubio et al. 2003;
Maskos et al. 2005). Evidence from neuroanatomical, elec-
trophysiological, and behavioral studies supports a role for
these receptor subtypes in drug dependence and in processes
of learning and memory. The α7 subtype, because of its
high density in the hippocampus, the amygdale, or the
prefrontal cortex, seems to be strongly implicated in cogni-
tion (Buccafusco 2004; Levin and Simon 1998; Paterson
and Nordberg 2000), as among the brain structures, these
areas in particular have been revealed to be important for
memory regulation. In this context, the results suggest that
synaptic plasticity [i.e., long term potentiation (LTP) of
glutamatergic inputs] in the VTA underlies the influence of
nicotine on dopamine release in the nucleus accumbens and
prefrontal cortex, and this type of LTP may contribute to the
effects of nicotine on both learning and memory or addiction
(Mansvelder and McGehee 2000, 2002). Determining the
basic roles of nicotinic receptor subtypes throughout the
central nervous system for various aspects of cognitive
processes could facilitate nAChR-related therapeutic drug
development.
Concerning calcium homeostasis, it is well established
that CCAs are a heterogeneous group of drugs, which have
been subdivided into three classes based on chemical struc-
ture, pharmacokinetic profile, and therapeutic use: the
dihydropyridines (e.g., nimodipine, nicardipine, nifedipine),
the benzothiazapines (e .g . , d i l t iazem), and the
phenylalkylamines (e.g., verapamil). Drugs in all three
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classes block calcium entry through specific L-type chan-
nels in vascular and cardiac smooth muscle and on neuronal
cell bodies (Bean 1989; Miller 1987). All of the CCAs are
potent vasodilators, and their functional effect provides the
rationale for their use in the treatment of various cardiovas-
cular and neurological conditions, such as hypertension,
cerebrovascular disease, arrhythmias, and migraine
(Triggle 1999). However, little data are available about the
cognitive effects of CCAs, as only some dihydropyridine
derivatives were revealed to facilitate memory from several
types of learning in adult animals improving retention
and/or acquisition of memory-related processes (Genkova-
Papazova et al. 1997; Quartermain et al. 2001). Other stud-
ies have also suggested that the CCAs may be useful as
general cognitive enhancers on the basis of their ability to
improve learning and memory in neurologically normal
young adult animals. For instance, peripherally adminis-
tered CCAs have been shown to reverse experimentally
induced amnesias, to ameliorate the effects of brain lesions
on learning, or to improve spatial working memory (Finger
et al. 1990; Genkova-Papazova et al. 2001; Levy et al. 1991;
Zupan et al. 1996). Accordingly, in our study, amlodipine,
flunarizine, and nicardipine improved the acquisition of
memory, while amlodipine, nimodipine, nifedipine, and ve-
rapamil improved the consolidation of memory, after an
acute injection. However, the interpretation of these data is
complicated by the results of other studies, which have
either failed to find any effects of CCAs on learning or
retention or, on the contrary, have demonstrated impaired
cognition following their administration (Isaacson et al.
1989; Maurice et al. 1995; Nikolaev and Kaczmarek
1994). The inconsistency of the findings concerning
memory-related effects of CCAs suggests that memory en-
hancement after their administration in young animals may
not be a robust phenomenon and also indicates that the
variables, which determine their effect on learning and
memory processes, have yet to be completely identified.
Among the factors that may determine these effects, one
can propose route of administration, i.e., central vs. periph-
eral, dosing schedule, i.e., acute vs. chronic administration,
time of treatment, i.e., pre-training vs. post-training, as well
as other variables related to the kind of behavioral tasks used
to evaluate memory in animals. Indeed, the notion that
blockade of L-type VDCC can improve learning and mem-
ory appears paradoxical since it is widely accepted that
calcium influx into neurons is a major triggering event and
the first step in the cascade of biochemical reactions, which
underlies memory acquisition and storage (Izquierdo and
Medina 1997; Nicoll and Malenka 1995). Previous experi-
ments have hypothesized various explanations for that par-
adoxical enhancement of learning by L-type VDCC
blockers, including compensatory cellular changes, or their
nonspecific vasodilatory effects (Quevedo et al. 1998;
Vetulani et al. 1997). Importantly, this learning enhancement
has been observed repeatedly to disappear as the dose of L-
type VDCC antagonists increases, suggesting that it results
from modulation rather than complete blockade of the
channels.
In general, important role of L-type VDCC in learning
and memory is due to their involvement on the synaptic
plasticity (i.e., the long-lasting LTP) of hippocampal dentate
CA1 field, which considers being one possible cellular
mechanism underlying cognition (Bliss and Collingridge
1993; Lashgari et al. 2006). In vivo and in vitro electro-
physiological recordings of hippocampal neuron function
have demonstrated the presence of L-type VDCCs, and
activity-dependent Ca2+ entry into neurons to initiate LTP
in this region has been described (Freir and Herron 2003;
Morgan and Teyler 1999) The calcium entry into the neurons
that induces this phenomenon can occur when N-methyl-D-
aspartate (NMDA) receptors and VDCCs are activated
(Woodside et al. 2004), but the formation of short-term mem-
ories seems to be dependent upon activation of NMDA re-
ceptors, while activation of L-type VDCCs is required for
long-term memory formation (Borroni et al. 2000).
As recent electrophysiological study revealed the strong
affinity of amlodipine and verapamil to the nAChRs
(Jozwiak et al. 2005), the purpose of the present experiment
was also to attempt the memory-enhancing capability of
these two CCAs, using chronic, rather than acute, drug
administration. Relatively little preclinical research has in-
vestigated the effects of chronic administration of potential
cognitive enhancers/inhibitors, and it is therefore uncertain
whether drugs, which influence memory when administered
acutely, will, in all instances, continue to do so under con-
ditions of chronic administration. Our results showed that,
contrary to an acute administration, only verapamil, but not
amlodipine, after repetitive injections, impaired both acqui-
sition and consolidation of memory processes in mice.
Verapami l i s an L- type VDCC blocker of the
phenylalkylamine group, which has no major side effects
shared by other CCAs. There are controversial reports about
cognitive effect of chronic and acute administration of ve-
rapamil using different memory tests (Lashgari et al. 2006).
Previous studies demonstrated that, after an acute or chronic
injection, verapamil has no effect on acquisition of passive
avoidance and other learning tasks (Borroni et al. 2000;
Cain et al. 2002), but other studies have reported an impair-
ment in long-term memory after chronic verapamil admin-
istration in the eight-arm radial maze task (Woodside et al.
2004), similarly to our results. Moreover, central injection of
verapamil into the hippocampal dentate gyrus and amygdala
impairs memory retention and LTP induction in different
learning tasks (Freir and Herron 2003; Bauer et al. 2002).
On the contrary, some investigators have described a facil-
itatory role for verapamil in memory retrieval by linear maze
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learning task in mice (Quartermain et al. 2001). Other pos-
sible mechanisms of cognitive effects of verapamil can also
underlie its different effects as this CCA can also act as a
potent antagonist of 5-HT2 receptors, interacts with both α1
and α2 adrenoceptors, and has also been shown to inhibit
reuptake of 5-HT, dopamine, and noradrenaline into rat
forebrain synaptosomes (Borroni et al. 2000). As for
amlodipine, this compound is known to bind directly to
the α-subunit of the L-type VDCC channel complex
(Quartermain 2000; Quartermain et al. 1993), but also this
CCA has been shown to inhibit free radical-induced damage
to cell membrane independent of channel blockade (Mason
et al. 1999), suggesting as another possibility that these
properties might underlie the effect of amlodipine on mem-
ory enhancement after an acute injection (Paris et al. 2011),
as confirmed by our work.
Concerning the molecular mechanisms of CCAs/nicotine
interactions measured in the present work, increasing evi-
dence suggests that changes in calcium channel function
play an essential role in nicotine tolerance and dependence
development. Not surprisingly, L-type VDCC antagonists
have been shown, also in our recent works, to attenuate the
signs of nicotine, physical dependence in animals (Biala and
Weglinska 2005), as well as other behavioral effects of
nicotine, including its reinforcing and stimulant effects, like
the acquisition and the expression of nicotine-induced sensi-
tization and place preference including reinstatement phe-
nomenon (Biala 2003; Biala and Budzynska 2006, 2008;
Biala and Weglinska 2004). Our present results revealed that
flunarizine, nicardipine, amlodipine, verapamil, and
bupropion, considered to be a noncompetitive nicotinic-
receptor antagonist at α3β2, α4β2, and at α3β4
ganglionic-type of nicotinic receptors (Slemmer et al.
2000), all at the subthresold doses, significantly reversed
the nicotine-induced improvement of memory acquisition,
while flunarizine, verapamil, and bupropion, but not
nicardipine or amlodipine, significantly reversed the im-
provement of memory consolidation provoked by an acute
injection of nicotine, thus resulting in an increased TL2 time
compared with nicotine-treated group. Moreover, chronic
pretreatment of both verapamil and amlodipine, at the
subthresold, ineffective dose, significantly reversed the im-
provement of both acquisition and consolidation of memory
provoked by an acute injection of nicotine, thus resulting in
an increased TL2 time compared with saline-treated and
nicotine-challenged group. However, the interpretation of
these data and the observed difference in inhibitory actions
on nicotine-induced cognitive behaviors among CCAs is
complicated by other results of different studies in humans
and animals already mentioned, which have either failed to
find any effects of CCAs on cognition or, on the contrary,
have demonstrated impaired cognition following their ad-
ministration. Thus, the effect of CCAs chosen for our
experiments to deteriorate pathological conditions in AD
patients has not been confirmed in all above-mentioned
studies.
Previous studies with neuronal preparations have shown
that significant amounts of Ca2+ enter the neuron following
activation of nAChRs, causing a rise in Ca2+ concentration
(Barrantes et al. 1995), and this effect is sufficient to activate
calcium-dependent protein kinases, like, e.g., calcium-
dependent calmodulin protein kinase II (CaMKII; Damaj
2000). Furthermore, nAChR-mediated depolarization can
activate VDCCs, and this effect potentiates the primary
Ca2+ signals generated by nicotinic receptor activation
(Dajas-Bailador and Wonnacott 2004). It is almost certain
that enhanced calcium-dependent CaMKII activity can
phosphorylate and modulate functions of other proteins that
could play some role in modulating nicotine memory en-
hancing effects.
From both electrophysiological and behavioral studies,
we can better understand the downstream effects of nAChR
activation, including activation of VDCCs. As already not-
ed, nicotinic receptors are found throughout the brain where
they act presynaptically to increase synaptic efficacy by
increasing neurotransmitter release, probably by recruiting
calcium channels to engage downstream signaling event. In
both the central and peripheral nervous systems, nAChRs
are inhibited by several drugs that are commonly considered
to be specific for L-type calcium channels. In turn, evidence
suggests that activation of postsynaptic nAChRs, also by
nicotine by itself, can activate L-type VDCCs engaging
downstream signaling mechanisms including the above-
mentioned CaMKII pathway, to induce LTP and alter
CREB-dependent gene expression (Levin et al. 2006;
Wheeler et al. 2006). Moreover, L-type VDCC can also
oppose the effects of nAChR activation. CCAs block cur-
rents through VDCC either by preventing channel activation
or acting as direct pore blockers; however, L-type CCAs
modulators are also noncompetitive inhibitors at nAChRs
by slow open-channel blockade and/or by promoting
nAChR desensitization (Adam and Henderson 1990;
Buisson and Bertrand 1998; Jozwiak et al. 2005), as can
be confirmed by the present research.
Conclusion
To sum up, our data indicate that nicotine and CCAs chosen
were capable of producing significant improvement in mem-
ory effect after an acute injection in the mEPM test in mice.
Moreover, we revealed that both bupropion, a nAChR an-
tagonist, and CCAs attenuated nicotine-induced improve-
ment in memory acquisition and/or consolidation. Our
results further established that interactions of L-type
VDCC antagonists with nAChRs can have a major impact
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on cellular events downstream of nAChR activation by
nicotine. However, the role of CCAs interactions with
nAChRs in signaling has not been examined in detail yet.
The present findings are the first to demonstrate that, at
concentrations typically used to block L-type VDCC,
these antagonists can modify (i.e., improve after an acute
administration or decrease after chronic injection)
memory-related processes, and can block the memory
enhancing effects of nicotine by inhibiting nAChR cur-
rents and downstream signaling. As such, it is possible to
speculate on the influence of calcium homeostasis on the
adaptive changes underlying the cognitive effects of nic-
otine, but further research is necessary in order to deter-
mine their efficacy and safety.
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